Angiographic performance of everolimus‐eluting stents for the treatment of coronary in‐stent restenosis in daily practice

The present study aims to analyze the angiographic anti‐restenotic performance of durable polymer everolimus‐eluting stents (EES) for the treatment of in‐stent restenosis (ISR) in daily practice.

[1]  H. Schunkert,et al.  Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study) , 2019, European heart journal.

[2]  Takeshi Kimura,et al.  Post-intervention minimal stent area as a predictor of target lesion revascularization after everolimus-eluting stent implantation for in-stent restenosis: a single-center observational study. , 2019, Coronary artery disease.

[3]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[4]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[5]  M. Beijk,et al.  A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial. , 2017, JACC. Cardiovascular interventions.

[6]  G. Stone,et al.  Coronary balloon angioplasty, stents, and scaffolds , 2017, The Lancet.

[7]  Wei-wei Zhu,et al.  Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis , 2017, BMC Cardiovascular Disorders.

[8]  B. García del Blanco,et al.  Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials , 2016, Circulation. Cardiovascular interventions.

[9]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[10]  R. Virmani,et al.  Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. , 2015, European heart journal.

[11]  A. Kastrati,et al.  Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis , 2015, The Lancet.

[12]  A. Íñiguez,et al.  A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. , 2015, Journal of the American College of Cardiology.

[13]  K. Stangl,et al.  Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: Results of the Randomized BIOFLOW-II Trial , 2015, Circulation. Cardiovascular interventions.

[14]  H. Schunkert,et al.  Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. , 2015, European heart journal.

[15]  Fernando Alfonso,et al.  Current treatment of in-stent restenosis. , 2014, Journal of the American College of Cardiology.

[16]  Samin K. Sharma,et al.  Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). , 2014, The American journal of cardiology.

[17]  M. Joner,et al.  Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  M. Joner,et al.  Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography , 2013, Heart.

[19]  D. Holmes,et al.  Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.

[20]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[21]  Seung‐Jung Park,et al.  Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials , 2012, Clinical Research in Cardiology.

[22]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[23]  A. Colombo,et al.  Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.

[24]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[25]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[26]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.